WUXI APPTEC (02359) announced that the Company (together with its subsidiaries, collectively referred to as the "Group") expects both revenue and net profit attributable to the Company's shareholders for the year ending December 31, 2025 (the "Current Period") to increase compared to the same period in the previous year (the "Corresponding Period Last Year").
The Company anticipates achieving revenue of approximately RMB 454.5617 billion for the Current Period, representing a year-on-year increase of about 15.84%, with revenue from continuing operations growing by approximately 21.40%.
It is expected that the Company will achieve an adjusted non-IFRS net profit attributable to shareholders (hereinafter referred to as "Adjusted Net Profit") of approximately RMB 14.957 billion for the Current Period, an increase of about 41.33% year-on-year.
The Company forecasts a net profit attributable to shareholders, excluding non-recurring gains and losses, of approximately RMB 13.241 billion for the Current Period, up about 32.56% year-on-year; the difference in growth rate compared to the Adjusted Net Profit is primarily attributed to foreign exchange fluctuations.
Net profit attributable to the Company's shareholders for the Current Period is expected to be approximately RMB 19.151 billion, surging about 102.65% year-on-year, which includes investment income from the partial divestment of an associate company and the spin-off of certain business segments.
Basic earnings per share for the Current Period are projected to be approximately RMB 6.70 per share, an increase of about 104.27% year-on-year.
The Company continues to focus on its unique, integrated, end-to-end CRDMO (Contract Research, Development, and Manufacturing) business model, capitalizing on the certainty of client demand for enablement, continuously expanding new capabilities, building new capacity, and optimizing production processes and operational efficiency to drive sustained and steady business growth, efficiently empowering clients and committing to bringing more new and effective medicines to patients globally.
The impact of non-recurring items on net profit attributable to the Company's shareholders for the Current Period primarily stems from: the net gain from the sale of a portion of the held shares in WuXi XDC Cayman Inc., estimated at approximately RMB 4.161 billion; and the net gain from the sale of 100% equity interests in Shanghai Kantar Healthdata Clinical Research Co., Ltd. and Shanghai Wuxi Jinshi Pharmaceutical Technology Co., Ltd., estimated at approximately RMB 1.434 billion.
Comments